Description:
ARQ-087, also known as Derazantinib, is an oral fibroblast growth factor receptor (FGFR) inhibitor with antitumor property. FGFR plays a role in the regulation of key cellular behaviors including proliferation, cell differentiation and so on. FGFR dysregulation is considered as a driver in multiple cancers. ARQ 087 binds to FGFR and effectively inhibits the activation of FGFR thus can suppress tumorigenesis and tumor growth.
- Molecular Weight:468.576
- Purity:≥98%
Molecular Formula:
C29H29FN4O
Canonical SMILES:
COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
InChI:
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
InChIKey:
KPJDVVCDVBFRMU-AREMUKBSSA-N
Solubility:
Soluble in DMSO
Appearance:
Solid powder
Synonyms:
ARQ 087; ARQ087; ARQ-087; Derazantinib; (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Weitere Informationen finden Sie
hier